Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies
April 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa Pharmaceuticals PLC (Nasdaq: BDRX)...
Clinical Trial
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the...
Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology...
AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability
Med Tech segment delivered its sixth consecutive quarter of double-digit growth Strong adjusted EBITDA Third consecutive quarter the Company raised...
MedMira Reports Second Quarter Results FY2025
HALIFAX, NS / ACCESS Newswire / April 1, 2026 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results...
Xtalks Announces its Life Science Webinar Calendar for April 2026
Upcoming free, educational webinars from Xtalks will feature topics in cell and gene therapy, clinical trials, commercialization & HEOR, drug...
Leverage Cognitive Data to Improve Sleep-Wakefulness Drug Evaluation, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn the importance of measuring cognition in sleep medicine trials. The featured speaker will share considerations...
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., April 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease...
Red Light Holland to Support University of California San Francisco’s Global Psychedelic Study Through Filament Health’s Clinical Network
Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light"...
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
PARAMUS, NJ, April 01, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying...
FeraMAX is Canada’s Top-Ranked Iron Supplement for 11 Consecutive Years
MISSISSAUGA, Ontario, April 01, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that FeraMAX®...
Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
Randomized phase of XanaMIA pivotal trial of oral Xanamem 10 mg remains on track for topline final results in November...
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
Funding will support ongoing development of APR-1051, including expansion into selected patient populations where WEE1 mechanism is well suitedDOYLESTOWN, Pa.,...
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
Bezuclastinib NDA submitted under the FDA’s RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted...
Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology...
Trevi Therapeutics to Participate in Upcoming Events
NEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the...
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural...
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
SHELTON, CT / ACCESS Newswire / April 1, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that a...
Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset
Provides guidance on interpretation of Topline dataset and confirms focus on drug-driven efficacy in non-melanoma skin cancerPHILADELPHIA, April 01, 2026...
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
- Poster on previously shared positive results from DELIVER clinical trial in Duchenne muscular dystrophy (DMD) contextualizes observed clinical measures...